CLSD Valuation
Clearside Biomedical Inc
$
0.879
- Overview
- Forecast
- Valuation
CLSD Relative Valuation
CLSD's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, CLSD is overvalued; if below, it's undervalued.
Historical Valuation
No Data
Competitors Valuation Multiple
The average P/S ratio for CLSD's competitors is 8.77, providing a benchmark for relative valuation. Clearside Biomedical Inc Corp (CLSD) exhibits a P/S ratio of 40.77, which is 364.89% above the industry average. Given its robust revenue growth of 913.04%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
People Also Watch
NVDA
NVIDIA Corp
135.400
USD
+0.42%
MSFT
Microsoft Corp
454.270
USD
+0.25%
META
Meta Platforms Inc
640.340
USD
-0.55%
AVGO
Broadcom Inc
228.610
USD
-1.73%
TSLA
Tesla Inc
349.980
USD
+2.09%
AAPL
Apple Inc
211.260
USD
-0.09%
ORCL
Oracle Corp
160.490
USD
+0.68%
WMT
Walmart Inc
98.240
USD
+1.96%
AMZN
Amazon.com Inc
205.590
USD
+0.20%
XOM
Exxon Mobil Corp
108.190
USD
-0.36%
FAQ
Is Clearside Biomedical Inc (CLSD) currently overvalued or undervalued?
Clearside Biomedical Inc (CLSD) is now in the Undervalued zone, suggesting that its current forward PS ratio of 40.77 is considered Undervalued compared with the five-year average of 106.05. The fair price of Clearside Biomedical Inc (CLSD) is between 1.78 to 3.44 according to relative valuation methord. Compared to the current price of 0.88 USD , Clearside Biomedical Inc is Undervalued By 50.56% .
What is Clearside Biomedical Inc (CLSD) fair value?
How does CLSD's valuation metrics compare to the industry average?
What is the current P/B ratio for Clearside Biomedical Inc (CLSD) as of May 19 2025?
What is the current FCF Yield for Clearside Biomedical Inc (CLSD) as of May 19 2025?
What is the current Forward P/E ratio for Clearside Biomedical Inc (CLSD) as of May 19 2025?